4325 related articles for article (PubMed ID: 6469514)
1. Preclinical evaluation of toxicity and therapeutic efficacy of a stabilized cytostatic metabolite of cyclophosphamide (ASTA Z 7557, INN mafosfamide).
Klein HO; Wickramanayake PD; Christian E; Coerper C
Invest New Drugs; 1984; 2(2):191-9. PubMed ID: 6469514
[TBL] [Abstract][Full Text] [Related]
2. Antineoplastic activity of ASTA Z 7557 (NSC-345842, INN mafosfamide) on transplantable murine tumors.
Atassi G; Hilgard P; Pohl J
Invest New Drugs; 1984; 2(2):169-73. PubMed ID: 6469511
[TBL] [Abstract][Full Text] [Related]
3. A comparative study of therapeutic activity, myelotoxicity and DNA damage in the bone marrow of mice after cyclophosphamide and ASTA Z 7557 (INN mafosfamide).
Berger MR; Bedford P; Zeller WJ; Kaufmann M
Invest New Drugs; 1984; 2(2):181-6. PubMed ID: 6469513
[TBL] [Abstract][Full Text] [Related]
4. Antineoplastic activity of ASTA Z 7557 (INN mafosfamide) in transplanted and autochthonous experimental rodent tumors.
Zeller WJ; Berger MR; Matys R; Schuhmacher J
Invest New Drugs; 1984; 2(2):175-80. PubMed ID: 6469512
[TBL] [Abstract][Full Text] [Related]
5. Cyclophosphamide and iphosphamide against Lewis lung carcinoma: evaluation of toxic and therapeutic effects.
Greco C; Corsi A; Caputo M; Cavallari A; Calabresi F
Tumori; 1979 Apr; 65(2):169-80. PubMed ID: 462569
[TBL] [Abstract][Full Text] [Related]
6. Comparative effects of ASTA Z 7557 (INN mafosfamide) and cyclophosphamide on hematopoiesis in mice.
Nowrousian MR; Schmidt CG
Invest New Drugs; 1984; 2(2):207-13. PubMed ID: 6469516
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of optical isomers of cyclophosphamide, ifosfamide and trofosfamide as compared to clinically used racemates.
Kuśnierczyk H; Radzikowski C; Paprocka M; Budzyński W; Rak J; Kinas R; Misiura K; Stec W
J Immunopharmacol; 1986; 8(4):455-80. PubMed ID: 3805744
[TBL] [Abstract][Full Text] [Related]
8. Effect of forphenicinol, a small molecular immunomodifier, in combination with cyclophosphamide on growth of and immunity to syngeneic murine tumors.
Nitta K; Tanaka T; Takeuchi M
Cancer Treat Rep; 1985 Mar; 69(3):285-91. PubMed ID: 3978657
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effects of single-push or fractionated injections or continuous infusion of oxazaphosphorines (cyclophosphamide, ifosfamide, Asta Z 7557).
Klein HO; Wickramanayake PD; Christian E; Coerper C
Cancer; 1984 Sep; 54(6 Suppl):1193-203. PubMed ID: 6432305
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide-adriamycin combination chemotherapy of transplantable murine tumors.
Corbett TH; Griswold DP; Mayo JG; Laster WR; Schabel FM
Cancer Res; 1975 Jun; 35(6):1568-73. PubMed ID: 1131824
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and toxicity of 4-(2-sulfonatoethylthio)-cyclophosphamide cyclohexylamine salt (ASTA Z 7557, INN mafosfamide) after intraperitoneal administration to mice.
Roberts JD; Hacker MP; Newman RA; McCormack JJ; Krakoff IH
Invest New Drugs; 1984; 2(2):215-20. PubMed ID: 6469517
[TBL] [Abstract][Full Text] [Related]
12. Autologous bone marrow transplantation for acute leukemia using transplant chemopurified with metabolite of oxazaphosphorines (ASTA Z 7557, INN mafosfamide). First clinical results.
Hervé P; Cahn JY; Plouvier E; Flesch M; Tamayo E; Leconte des Floris R; Peters A
Invest New Drugs; 1984; 2(2):245-52. PubMed ID: 6381384
[TBL] [Abstract][Full Text] [Related]
13. Antiproliferative activity of 2-[N, N-bis-(2-chloroethyl)-amino]-4-[2-sulfonato-ethylthio]-tetrah ydr o-2H-1 , 3,2-oxazaphosphorine-2-oxide cyclohexamine (ASTA Z 7557, INN mafosfamide) against human and murine tumor cells in vitro.
Kovach JS; Svingen PA
Invest New Drugs; 1984; 2(2):155-9. PubMed ID: 6469509
[TBL] [Abstract][Full Text] [Related]
14. Drug-tumor sensitivity matching procedure using diffusion chambers in vivo.
Cain BF; Calveley SB; Boreham BA; West C; Price NA; Walker DJ; Churchouse MJ
Cancer Chemother Rep; 1974; 58(2):189-205. PubMed ID: 4857364
[No Abstract] [Full Text] [Related]
15. Effect of dose, schedule, and route of administration on the in vivo toxicity and antitumor activity of two activated sulfhydryl derivatives of cyclophosphamide.
Ramonas LM; Erickson LC; Ringsdorf H; Zaharko DS
Cancer Res; 1980 Oct; 40(10):3704-8. PubMed ID: 7438053
[TBL] [Abstract][Full Text] [Related]
16. Effect of potentiated antibodies to cyclophosphamide on the development of tumors and effectiveness of cytostatic therapy under experimental conditions.
Amosova EN; Zueva EP; Razina TG; Krylova SG; Shilova NV; Epstein OI
Bull Exp Biol Med; 2003 Jan; 135 Suppl 7():54-6. PubMed ID: 12949650
[TBL] [Abstract][Full Text] [Related]
17. Tumor-associated macrophages stimulate the proliferation of murine tumor cells surviving treatment with the oncolytic cyclophosphamide analogue Asta Z-7557: in vivo implications.
Evans R; Duffy T; Cullen RT
Int J Cancer; 1984 Dec; 34(6):883-90. PubMed ID: 6511127
[TBL] [Abstract][Full Text] [Related]
18. Experimental toxicology of ASTA Z 7557 (INN mafosfamide).
Pohl J; Hilgard P; Jahn W; Zechel HJ
Invest New Drugs; 1984; 2(2):201-6. PubMed ID: 6469515
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity and cross-resistance of carmethizole hydrochloride in preclinical models in mice.
Waud WR; Plowman J; Harrison SD; Dykes DJ; Anderson WK; Griswold DP
Cancer Chemother Pharmacol; 1992; 30(4):261-6. PubMed ID: 1322803
[TBL] [Abstract][Full Text] [Related]
20. Selective antimetastatic treatment--current status and future prospects.
Spreafico F; Garattini S
Cancer Treat Rev; 1974 Dec; 1(4):239-50. PubMed ID: 4619577
[No Abstract] [Full Text] [Related]
[Next] [New Search]